글로벌 연구동향
방사선종양학
- 2023년 02월호
[Breast Care (Basel) .] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer이화의대 / 정원근, 김규보, 문병인*
- 출처
- Breast Care (Basel) .
- 등재일
- 2022 Dec
- 저널이슈번호
- 17(6):561-566. doi: 10.1159/000525838. Epub 2022 Jul 6.
- 내용
Abstract
Purpose: The purpose of this study was to evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer according to the risk group using EndoPredict (EP) score.Patients and methods: Between 2015 and 2019, 207 patients with ER+/HER2- pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. The EPclin score, which combines the molecular EP score with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.3.
Results: There were 154 and 53 patients in the EPclin low- and high-risk groups, respectively. Forty-one patients (81.1%) of the high-risk group received adjuvant chemotherapy, while only 1 (0.6%) of the low-risk group did. With a median follow-up of 54.1 months (range 8.2-76.6), the 5-year disease-free survival rates of low- and high-risk groups were 100% and 88.9%, respectively (p < 0.001).
Conclusions: The EPclin score was associated with recurrences in ER+/HER2- early breast cancer.
Affiliations
Wonguen Jung 1, Kyubo Kim 1, Byung-In Moon 2
1Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
2Department of Surgery, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
- 키워드
- Breast cancer; EndoPredict; Radiotherapy; Treatment outcome.
- 덧글달기
- 이전글 [Medicine (Baltimore) .] Modulated electrohyperthermia in locally advanced cervical cancer: Results of an observational study of 95 patients
- 다음글 [Int J Cancer.] Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study